Michael German, MD University of California, San Francisco, San Francisco, CA
- Status: Completed
- Year(s): 2014
- Grant Type: Investigator
- Research Type: Translational
- Primary Tumor Site: Pancreas
- Area of Inquiry: Signaling/drug targets
To test an FDA approved inhibitor of Mek1/2 (FDA approved for melanoma) in preclinical models of neuroendocrine tumors. The results will provide insight into the unique mechanisms that drive neuroendocrine cancer growth. Positive results of an already approved drug could speed the path from the bench-to-bedside to pave the way for clinical trials.
Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.
- City: San Francisco
- State: California
- Grant Duration: 2 years
- Grant Partner: American Association for Cancer Research (AACR)
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.